Laird Barry J A, Fallon Marie, Hjermstad Marianne J, Tuck Sharon, Kaasa Stein, Klepstad Pål, McMillan Donald C
Barry J.A. Laird, Marianne J. Hjermstad, Stein Kaasa, and Pål Klepstad, Norwegian University of Science and Technology; Pål Klepstad, Trondheim University Hospital, Trondheim; Marianne J. Hjermstad and Stein Kaasa, Oslo University Hospital, Oslo, Norway; Barry J.A. Laird, Marie Fallon, and Sharon Tuck, University of Edinburgh, Edinburgh; and Donald C. McMillan, University of Glasgow, Glasgow, United Kingdom.
J Clin Oncol. 2016 Aug 10;34(23):2769-75. doi: 10.1200/JCO.2015.65.7742. Epub 2016 Jun 27.
Quality of life is a key component of cancer care; however, the factors that determine quality of life are not well understood. The aim of this study was to examine the relationship between quality of life parameters, performance status (PS), and the systemic inflammatory response in patients with advanced cancer.
An international biobank of patients with advanced cancer was analyzed. Quality of life was assessed at a single time point by using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C-30 (EORTC QLQ-C30). PS was assessed by using the Eastern Cooperative Oncology Group (ECOG) classification. Systemic inflammation was assessed by using the modified Glasgow Prognostic Score (mGPS), which combines C-reactive protein and albumin. The relationship between quality of life parameters, ECOG PS, and the mGPS was examined.
Data were available for 2,520 patients, and the most common cancers were GI (585 patients [22.2%]) and pulmonary (443 patients [17.6%]). The median survival was 4.25 months (interquartile range, 1.36 to 12.9 months). Increasing mGPS (systemic inflammation) and deteriorating PS were associated with deterioration in quality-of-life parameters (P < .001). Increasing systemic inflammation was associated with deterioration in quality-of-life parameters independent of PS.
Systemic inflammation was associated with quality-of-life parameters independent of PS in patients with advanced cancer. Further investigation of these relationships in longitudinal studies and investigations of possible effects of attenuating systemic inflammation are now warranted.
生活质量是癌症护理的关键组成部分；然而，决定生活质量的因素尚未得到充分理解。本研究的目的是探讨晚期癌症患者生活质量参数、体能状态（PS）与全身炎症反应之间的关系。
对一个国际晚期癌症患者生物样本库进行了分析。使用欧洲癌症研究与治疗组织生活质量问卷C-30（EORTC QLQ-C30）在单个时间点评估生活质量。使用东部肿瘤协作组（ECOG）分类评估PS。使用结合了C反应蛋白和白蛋白的改良格拉斯哥预后评分（mGPS）评估全身炎症。研究了生活质量参数、ECOG PS和mGPS之间的关系。
有2520例患者的数据可用，最常见的癌症是胃肠道癌（585例患者[22.2%]）和肺癌（443例患者[17.6%]）。中位生存期为4.25个月（四分位间距，1.36至12.9个月）。mGPS升高（全身炎症）和PS恶化与生活质量参数恶化相关（P <.001）。全身炎症增加与生活质量参数恶化相关，且与PS无关。
在晚期癌症患者中，全身炎症与生活质量参数相关，且与PS无关。现在有必要在纵向研究中进一步研究这些关系，并研究减轻全身炎症可能产生的影响。
